Charles River Laboratories to draw on euro revolver for acquisition

By Sara Rosenberg

New York, March 13 - Charles River Laboratories International Inc. plans on using borrowings under its existing euro-denominated revolving credit facility and cash on hand to fund the €129 million acquisition of the contract research organization services division of Galapagos NV, according to a news release.

Closing is expected early in the second quarter, subject to customary conditions.

Charles River is a Wilmington, Mass.-based drug development company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.